Pre-clinical Development of a Novel Second Generation Chemotherapeutic for Cancer Therapy

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1038660

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Cancer cells have a high iron requirement for DNA synthesis and many clinical trials have shown that iron chelators are effective anti-cancer drugs. Their potential to act as anti-tumour agents has been confirmed by the entrance of the iron chelator, Triapine, into widespread NCI clinical trials. In this NHMRC Development Grant, we will perform toxicological studies to enable clinical trials of our most potent and selective anti-cancer agent to commence.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2014

Funding Scheme: Development Grants

Funding Amount: $584,907.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Basic Pharmacology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

drug development | medicinal chemistry | pharmaceutical treatment | pharmaceutics | pharmacology

Related Links